


ISSN: 2249-7137 Vol. 11, Issue 10, October 2021 Impact Factor: SJIF 2021 = 7.492



ACADEMICIA

An International Multidisciplinary Research Journal

(Double Blind Refereed & Peer Reviewed Journal)



DOI: 10.5958/2249-7137.2021.02214.X

DRUG DISCOVERY: A COMPLETE REVIEW

Ms. Rinka Juneja*

*SOP, Sanskriti University, Mathura, Uttar Pradesh, INDIA Email id: rinka.pharmacy@sanskriti.edu.in

ABSTRACT

The drug business is one of the main actors driving the growth of the medicines, biotechnology & pharmacology sector. Drug discovery is the process through which medicines are discovered and developed. It is a technique which aims at finding a chemical therapeutically helpful in healing & treating illness. The process of drug discovery includes the identification of candidates, synthesis, characterisation, screening & tests for therapeutic effectiveness. Once a molecule has proven its usefulness in these tests, it will begin the process of medication development prior to clinical trials. Developing a new medication is a laborious & costly endeavor, despite exciting discoveries and multibillion dollar expenditures for new drug development is silently facing turmoil. Currently, all current treatments collectively reach only about 400 distinct pharmacological targets. It is predicted that there are at least 10 times as many potential pharmacological targets that could be explored for future therapeutic treatment in the future.

KEYWORDS: Clinical trial, Clinical trials, Drug discovery, Drug development, Potential drug targets.

REFERENCES

- **1.** A. Mongia and A. Majumdar, "Drug-target interaction prediction using Multi Graph Regularized Nuclear Norm Minimization," *PLoS One*, 2020, doi: 10.1371/journal.pone.0226484.
- **2.** H. Giersiefen, R. Hilgenfeld, and A. Hillisch, "Modern methods of drug discovery: an introduction.," *EXS.* 2003, doi: 10.1007/978-3-0348-7997-2_1.
- **3.** T. R. Ngara and H. Zhang, "Recent Advances in Function-based Metagenomic Screening," *Genomics, Proteomics and Bioinformatics*. 2018, doi: 10.1016/j.gpb.2018.01.002.



ISSN: 2249-7137 Vol. 11, Issue 10, October 2021 Impact Factor: SJIF 2021 = 7.492

- **4.** Sandra V. B. Jardim*, "The Electronic Health Record and its Contribution to Healthcare Information Systems Interoperability," *Procedia Technol.*, 2013.
- 5. J. Eckstein, "ISOA / ARF Drug Development Tutorial," *Development*, 2006.
- **6.** Y. Wang, J.-F. Chiu, and Q.-Y. He, "Proteomics in Computer-Aided Drug Design," *Curr. Comput. Aided-Drug Des.*, 2006, doi: 10.2174/1573409052952260.
- **7.** V. S. Rao, S. K. Das, V. J. Rao, and G. Srinubabu, "Recent developments in life sciences research: Role of bioinformatics," *African Journal of Biotechnology*. 2008, doi: 10.4314/ajb.v7i5.58463.
- **8.** S. C. Gad, "Introduction: Drug Discovery in the 21st Century," *Drug Discovery Handbook*. 2005, doi: 10.1002/0471728780.
- **9.** S. Wang, T. B. Sim, Y. S. Kim, and Y. T. Chang, "Tools for target identification and validation," *Current Opinion in Chemical Biology*. 2004, doi: 10.1016/j.cbpa.2004.06.001.
- **10.** J. Drews, "Drug discovery: A historical perspective," *Science*. 2000, doi: 10.1126/science.287.5460.1960.